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Abstract: 
Background and aims: Crohn’s disease (CD) can involve any part of the gastrointestinal tract. We 
aimed to characterize clinical, endoscopic, histologic features and treatment outcomes of CD patients 
with oesophageal involvement. 
Methods: We collected cases through a retrospective multicentre European Crohn's and Colitis 
Organisation CONFER [COllaborative Network For Exceptionally Rare case reports] project. Clinical 
data were recorded in a standardized case report form. 
Results: A total of 40 patients were reported [22 males, mean (±SD, range) age at oesophageal CD 
diagnosis: 25 (±13.3, 10-71) years and mean time of follow-up: 67 (±68.1, 3-240) months]. 
Oesophageal involvement was established at CD diagnosis in 26 patients (65%) and during follow-up 
in 14. CD was exclusively located in the oesophagus in 2 patients. Thirteen patients (32.2%) were 
asymptomatic at oesophageal disease diagnosis. Oesophageal strictures were present in 5 patients and 
fistulizing oesophageal disease in one. Eight patients exhibited granulomas on biopsies. Proton-pump 
inhibitors (PPIs) were administered in 37 patients (92.5%). Three patients underwent endoscopic 
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dilation for symptomatic strictures and none oesophageal-related surgery. Diagnosis in pre-established 
CD resulted in treatment modifications in 9/14 patients. Clinical remission of oesophageal disease 
was seen in 33/40 patients (82.5%) after a mean time of 7 (±5.6, 1-18) months. Follow-up endoscopy 
was performed in 29/40 patients and 26/29 (89.7%) achieved mucosal healing.  
Conclusion: In this case series the endoscopic and histologic characteristics of isolated oesophageal 
CD were similar to those reported in other sites of involvement. Treatment was primarily 
conservative, with PPIs administered in the majority of patients and modifications in pre-existing 
IBD-related therapy occurring in two thirds of them. Clinical and endoscopic remission was achieved 
in more than 80% of the patients.   
 
Keywords: Crohn’s disease, Oesophagus 
 
 
Introduction 
Crohn’s disease (CD) is a lifelong disease arising from an interaction between genetic and 
environmental factors. It can involve any part of the gastrointestinal tract, but the most common 
locations are the terminal ileum and colon. Oesophageal involvement is not usual. Nevertheless, more 
than 100 cases of oesophageal CD have been published since the first report of Franklin and Taylor in 
19501-3. Prevalence of 0.3-10% is suggested in adults but population-based studies are lacking3-7. 
More frequent oesophageal involvement has been implicated in studies reporting on pediatric CD 
patients (4.2-42%)8,9. Wide variations are generally attributed to whether asymptomatic patients with 
histological involvement are included in the analysis. Gastroduodenoscopy is not considered a pre-
requisite for CD mapping in most guidelines and especially in asymptomatic adults9,10.  
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Oesophageal CD can present as an erosive–ulcerative esophagitis, oesophageal stricture, or fistula, 
thus sharing many features of other more common diseases of the oesophagus (reflux oesophagitis, 
infection, drug-induced, related to malignancy or autoimmune diseases). The histologic features of 
oesophageal CD may be nonspecific further adding on diagnostic challenge. The optimal treatment of 
oesophageal CD is unknown because controlled trials are lacking. Most physicians use proton pump 
inhibitors (PPI) as an add-on regimen to conventional therapy and have a lower threshold for starting 
anti-TNF therapy compared to disease located elsewhere, given the expected poor prognosis10. 
We aimed to describe diagnostic work-up, interventions and outcome of a series of patients with CD 
located in the oesophagus.  
 
 
 
 
 
 
 
Materials and Methods  
Study design 
The European Crohn’s and Colitis Organisation (ECCO) CONFER [COllaborative Network For 
Exceptionally Rare case reports] projects are based on an initiative introduced by ECCO to support 
individual investigators in identifying, assembling and reporting together rare Inflammatory Bowel 
Disease (IBD) cases of clinical relevance, which are otherwise seldom reported. The core of 
CONFER methodology is selecting certain topics worthy of investigation out of case proposals 
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submitted by physicians involved with IBD. The Steering Committee makes an initial selection, 
identifying those cases with the highest scientific interest and proximity to the purpose of CONFER 
project. A Feasibility Network, comprised of 30-35 high volume IBD centers around the globe, is 
asked to identify similar cases and the final decision is again taken by the Steering Committee based 
on the outcome of networking. This topic then becomes a CONFER project. ECCO supports 
dissemination of a call to identify similar cases encountered by IBD physicians worldwide using 
several tools; announcements in the ECCO annual congress and in national and international IBD 
meetings across Europe, e-mailing to all ECCO members, posting in ECCO website and ECCO 
eNews, flyers and personal communication between ECCO members. Physicians are then prompted 
to report their case(s) using a pre-determined standardized case report form. The call for the present 
case series was entitled “Oesophageal Crohn's Disease”. No financial support or input in the 
collection of data, the analysis or the publication of the data collected is provided by ECCO. ECCO 
and/or any of its staff members may not be held liable for any information published in good faith in 
the ECCO CONFER articles.  
 
Patients and procedures 
All CD patients with oesophageal involvement diagnosed either throughout the course of CD or at 
diagnosis were eligible for inclusion in this study. Diagnosis of oesophageal CD was based on clinical 
presentation, endoscopic appearance and histological findings10. Oesophageal involvement was 
histologically supported in all patients reported in this case series. Data were collected using a case 
report form, which was divided into two main sections. Section 1 included patient (epidemiological 
data, past medical history, alcohol consumption/smoking, family history) and disease (date of 
diagnosis, Montreal classification, extraintestinal manifestations and treatment) characteristics. 
Section 2 included a description of oesophageal CD: disease location, endoscopic and histological 
findings, treatment of CD at oesophageal diagnosis, interventions, treatment modifications and course 
of disease. Relevant laboratory and radiologic tests were also recorded. Data were collected and 
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analyzed anonymously and handled according to local regulations. Informed consent was obtained, 
where obligatory. 
 
Statistics 
All statistical analyses (frequencies, descriptive statistics) were done with SPSS 20.0 software 
package (IBM SPSS Statistics, Armonk, NY, USA).  
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Results 
Patients’ background information 
A total of 15 centers responded to our call and 50 cases were initially reported. Ten patients were 
excluded due to lack of compatible histologic data and thus 40 cases were included in the analysis. 
Patients’ characteristics are shown in Table 1. Mean (±SD, range) age at CD diagnosis was 23 years 
(±12.6, 3-71). Only 2 patients (5%) were current smokers. A family history of IBD was reported in 
7.5% of patients. CD was exclusively located in the upper GI tract in 4 patients and solely in the 
oesophagus in 2 while in the rest, ileal disease was present in 9 (22.5%), colonic in 3 (7.5%) and ileo-
colonic in 24 (60%) patients. Gastric involvement was generally seen in 15 patients (37.5%). Of 
those, only two had active Helicobacter pylori infection. Thirteen patients (32.5%) had received at 
least one anti-tumor necrosis factor (TNF) agent and six (15%) had undergone a CD-related surgery 
(partial small bowel resection, stricturoplasty, partial colectomy, ileo-cecal resection or rectal abscess 
drainage) prior to oesophageal involvement diagnosis. 
 
Oesophageal CD diagnosis 
Oesophageal disease characteristics are summarized in Table 2. Mean IBD duration until esophageal 
disease diagnosis was 2.9 (±5.7, 0.0–27.9) years, with a mean age at diagnosis of 25 (±13.3, 10-71) 
years. Oesophageal involvement was established at CD diagnosis in 26 patients (65%) and during 
follow-up in 14 (35%). Most patients had at least one additional test to exclude more common 
diagnoses (n=35, 87.5%); contrast esophageal examination in 12 patients (30%), Interferon Gamma 
Release Assay (IGRA) in 27 (67.5%), tuberculin skin test in 18 (45%), esophageal brushing for 
Candida spp in 11 (27.5%), an angiotensin converting enzyme test in 5 (12.5%), antibodies against 
human immunodeficiency virus (HIV) in 29 (72.5%), mycological infection staining on biopsy in 19 
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(47.5%), Ziehl–Nielsen stain in 11 (27.5%), polymerase chain reaction for Mycobacterium 
tuberculosis in 4 (10%), chest CT in 12 (30%), chest X-ray in 28 (70%), oesophageal manometry in 5 
(12.5%) or 24-hour oesophageal pH test in 5 (12.5%). Laboratory testing was abnormal in most of the 
patients at oesophageal disease diagnosis, with elevated C-reactive protein in 23 patients [mean 2.9 
(±1.9, 1.0-7.0) mg/dL] and elevated erythrocyte sedimentation rate in 24  [mean 44 (±18.4, 26.0-94.0) 
mm/h]. Sixteen patients (40%) had anemia [mean hemoglobin value 9.8 (±2.3, 6.0-12.0) g/dL].                                             
The most common symptom was dysphagia or odynophagia in 19 patients (47.5%). Thirteen patients 
(32.5%) were asymptomatic at oesophageal disease diagnosis. As mentioned before, esophageal CD 
was diagnosed during follow-up in 14 patients. Upper GI endoscopy was performed in these patients 
due to: dysphagia and/or odynophagia in 6, weight loss in 2, heartburn in 1, iron deficiency anemia in 
2, reassessment of pre-existing upper GI CD in 2 and in a pediatric patient with active disease. 
Distal oesophagus was the most common site of involvement, either alone (n=15, 37.5%) or as part of 
involvement of the entire oesophagus (n=10, 25%). There were several endoscopic findings, but 
erosions and small ulcers were more frequently seen (n=31, 77.5%). Interestingly, one patient 
presented with an oesophageal fistula. Representative pictures of endoscopic findings are shown in 
Figure 1.  
On histology, seventeen patients (42.5%) had acute and chronic inflammation while 12 (30%) were 
found to have chronic inflammation with predominantly lymphocytes and plasma cells. Non-caseating 
granulomas were less frequently seen (n=8, 20%). 
 
Oesophageal disease treatment and outcomes 
Thirty-four patients (85%) had an inflammatory phenotype of oesophageal CD and were treated with 
a variety of medications (Table 2). Treatment was decided not only upon esophageal CD activity but 
also on extraesophageal involvement. Most patients were treated with more than one drug (n=33, 
82.4%). Proton-pump inhibitors (PPIs, n=37, 92.5%) were administered in the majority of patients, 
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but only three were treated with PPI as monotherapy. Three patients underwent endoscopic dilation 
for symptomatic strictures and none CD-related oesophageal surgery. CD was active either clinically 
and/or endoscopically in the majority of patients at oesophageal involvement diagnosis (>80%).   
Interestingly, oesophageal disease diagnosed during CD follow-up (14/40) resulted in treatment 
modifications in 9/14 patients, excluding PPIs use, 6 of them also with extra-oesophageal clinical 
activity: 5 started systemic corticosteroids, 2 topical steroids (fluticasone), one anti-TNF and one 
methotrexate. Thirty-three patients (82.5%) were successfully treated with first line therapy and 
complete resolution of symptoms occurred after a mean time of 7 (±5.6, 1.0-18.0) months. Three 
patients required second line therapy for sustained clinical activity (two endoscopic interventions and 
one initiation of thiopurines). Three patients had symptomatic recurrence after initial clinical 
response, all beyond the first year after diagnosis, and regained remission after starting systemic 
corticosteroids, anti-TNF and undergoing esophageal dilatation, respectively. On last follow up, one 
patient had not achieved remission after multiple ther pies and active extra-oesophageal disease. 
Follow-up endoscopy was performed in 29 patients and 89.7% achieved mucosal healing. Of the 2 
patients with isolated oesophageal disease, one was treated only with PPI with complete symptomatic 
resolution while the other required combined endoscopic and medical therapy initially with PPI and 
systemic corticosteroids and subsequently administration of thiopurine and anti-TNF; both had 
achieved mucosal healing at last follow-up.   
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Discussion 
This is a retrospective, international study reporting a series of CD patients with oesophageal 
involvement. Although this study was not designed to assess the prevalence of oesophageal CD, we 
can infer that onset of this presentation may be under-recognized due to the infrequent performance of 
upper GI endoscopy in asymptomatic individuals with CD, especially adults.  
Diagnostic work up includes a combination of oesophageal-specific symptoms, a history of extra-
oesophageal CD, and endoscopic and histologic features that are supportive but not specific for CD. 
Almost one third of the patients in our series were asymptomatic while the rest complained of non-
specific symptoms like dysphagia/odynophagia, heartburn, vomiting, chest pain and weight loss, 
resembling gastro-oesophageal reflux disease, similar to previous reports.3, 5, 7 Most patients had at 
least one additional test to exclude more common diagnoses (87.5%). CD of the oesophagus is not 
difficult to diagnose in cases in which other segments of the digestive tract are simultaneously 
involved or in patients with a prior history of CD, but isolated oesophageal disease requires exclusion 
of more common diseases, so we suggest that in the absence of a previous diagnosis of CD, an 
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exclusion of GERD (based on pH impedance study), infectious oesophagitis (based on specific stains 
at least for Candida and Cytomegalovirus) and granulomatous diseases such as tuberculosis and 
sarcoidosis (based on imaging and laboratory tests) should be made. 
Endoscopic features are not pathognomonic. Wang et al. proposed that oesophageal CD progresses 
through three phases. The initial phase involves inflammation, edema, erosions and linear ulcers 
without significant symptoms, then there is a progression to stenotic lesions with mucosal bridges and 
finally  patients present with progressive dysphagia, odynophagia, vomiting and weight loss and 
severe complications on the ground of fibrotic strictures and fistulae.11 Distal superficial ulcers, 
erosions and/or erythema were common in our cohort as described in other reports.3, 5, 7 However, 
stenotic lesions necessitating interventions were uncommon and only one patient developed a fistula.  
Histological features are also not always compatible with CD. In our cohort, chronic inflammation 
was the most common presentation; eight patients (20%) had non-caseating granulomas in the setting 
of chronic inflammation, a higher rate than the one reported in the literature (7-9%), perhaps due to 
the inclusion of pediatric patients as granuloma formation is more often seen in younger patients, and 
mainly in the severe, active penetrating disease.12,13  
CD limited to the oesophagus is rare and has been described in case reports.6,11,14,15 In our cohort there 
were only 2 cases. Oesophageal involvement was established at CD diagnosis in two thirds of the 
patients (65%) and during follow-up in one third (35%). Almost half of the patients demonstrated 
perianal disease, which is also in line with previous reports.16 One third of the cohort had extra-
intestinal manifestations, slightly less than global data for CD, which can also be justified by the 
inclusion of pediatric patients.17 
There are limited data on the most suitable management of oesophageal CD due its rarity and the 
frequent coexistence of distal disease which leads to the use of standardized therapeutic protocols. 
ECCO guidelines suggest treating mild esophageal CD with PPI only and more severe or refractory 
disease with systemic corticosteroids or an anti-TNF-based strategy.10 PPI-induced acid suppression is 
thought to play a facilitating role in esophageal mucosal healing, similar to what happens with ulcers 
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provoked from endoscopic submucosal dissection. De Felice et al suggested treating oesophageal CD 
based on disease behavior.3 This cohort confirms this strategy with the vast majority of patients being 
treated with a PPI and less patients with more complicated or persistently active disease at 
oesophageal involvement diagnosis requiring step-up therapies. Oesophageal disease diagnosed 
during follow-up resulted in medical treatment modifications in 64.3% of patients, two thirds of 
whom (66.7%) had also extra-oesophageal clinical activity. 
The limitation of the CONFER methodology should be acknowledged, as it relies on voluntary 
submission of cases by physicians responding to ECCO calls, which could introduce geographical and 
other selection biases. However, we believe this caveat is offset by the benefits of this methodology 
for identifying and reporting larger case series of rare events, which are otherwise seldom reported in 
a single case-report format. The sample size is relatively small and thus no risk factors or predictors 
can be investigated. Follow-up endoscopy was not available in all patients.  
In conclusion, oesophageal involvement can be detected either at CD diagnosis or during follow-up, 
manifesting as the only site of CD location in rare cases. Characteristics are similar to those of other 
sites of involvement and diagnosis can be challenging and performed even during CD being in 
remission. Optimal treatment is conservative but not consensual depending also on extra-oesophageal 
sites of involvement, with PPIs administered in the majority of patients and treatment modifications 
occurring frequently, when diagnosed at a later phase. Properly designed, ideally prospective studies 
are needed to identify more reliable diagnostic criteria and phenotypes of oesophageal CD that predict 
response to specific medical therapies. However, until further data are available, this needs to be a 
case-by-case decision. 
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Figure legend 
Figure 1: Endoscopic findings: A- focal erythematous spots, B- erosions, C and D- deep ulcerations, E 
and F- stenosis and pseudopolyps 
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Table 1. Patient demographics and Crohn’s disease characteristics 
Characteristic Patients (n=40) 
Mean (±SD, range) age at diagnosis (years) 23 (±12.6, 3-71) 
Gender 
Male 
Female 
 
22 (55%) 
18 (45%) 
Race 
Asian/Oriental  
Caucasian/White 
 
6 (15%) 
34 (85%) 
Ethnicity 
Hispanic or latino  
Non-Hispanic or non-latino 
 
5 (12.5%) 
35 (87.5%) 
Geographical spread 
Poland 
China 
The Netherlands 
 
8 (20%) 
3 (7.5%) 
4 (10%) 
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Portugal 
Spain 
Greece 
Switzerland  
Germany 
Italy 
Malta 
United Kingdom 
Israel 
3 (7.5%) 
2 (5%) 
6 (15%) 
4 (10%) 
3 (7.5%) 
2 (5%) 
2 (5%) 
2 (5%) 
1 (2.5%) 
Positive family history of IBD 3 (7.5%) 
Smoking 
Current 
Former 
Non-smoker 
 
2 (5%) 
 2 (5%) 
36 (90%) 
Montreal Classification – age 
<=16  
17-40  
 >40 
 
18 (45%) 
20 (50%) 
2 (5%) 
Montreal Classification – location   
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L1  
L2  
L3 
Isolated L4 
9 (22.5%) 
3 (7.5%) 
24 (60%) 
4 (10%) 
Montreal Classification – behavior 
B1 
B2 
B3 
 
22 (55%) 
8 (20%) 
10 (25%) 
Perianal disease 18 (45%) 
Extra-intestinal manifestations 
Ocular – uveitis / episcleritis 
Osteoarticular – peripheral arthropathy        
Skin – erythema nodosum 
Oral granulomatosis 
14 (35%) 
1 / 1 
5 
6 
3 
Prior IBD treatment  
5-aminosalicylic acid 
Systemic corticosteroids 
Anti-TNF 
Thiopurines 
 
14 (35%) 
12 (30%) 
13 (32.5%) 
16 (40%) 
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Methotrexate 
Surgery 
3 (7.5%) 
6 (15%) 
 
 
Table 2. Characteristics of oesophageal CD  
Characteristic Value (n=40) 
Age (±SD, range) at diagnosis (years) 25 (13.3, 10-71) 
Course of disease 
Oesophageal disease at diagnosis  
Oesophageal disease at follow-up 
 
26 (65%) 
14 (35%) 
Symptoms 
Dysphagia/Odynophagia  
Heartburn  
Vomiting  
Chest pain  
Weight loss  
Asymptomatic – Incidental finding at endoscopy 
 
19 (47.5%) 
8 (20%) 
3 (7.5%) 
8 (20%) 
8 (20%) 
13 (32.5%) 
Location 
Proximal  
 
6 (15%) 
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Mid  
Distal  
Entire oesophagus 
9 (22.5%) 
15 (37.5%) 
10 (25%) 
Endoscopic findings 
Erosions or small ulcers  
Deep ulceration  
Patchy erythema  
Multiple focal erythematous spots  
Stricture  
Fistula 
 
31 (77.5%) 
7 (17.5%) 
6 (15%) 
6 (15%) 
5 (12.5%) 
1 (2.5%) 
Oesophageal histology 
Presence of granulomas  
Acute and chronic inflammation  
Chronic inflammation  
Acute inflammation 
 
8 (20%) 
17 (42.5%) 
12 (30%) 
2 (5%) 
IBD disease activity at oesophageal CD diagnosis 
Clinically active     
Endoscopically activity    
CT or MR enterography evidence of disease 
 
                  33 (84.6%) 
35 (89.7%) 
21 (53.8%) 
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Treatment after diagnosing of oesophageal CD 
Proton Pump Inhibitor  
5-aminosalicylic acid 
Systemic corticosteroids 
Anti-TNF 
Thiopurines 
Enteral nutrition 
Endoscopic dilation 
 
37 (92.5%) 
16 (40%) 
21 (52.5%) 
23 (57.5%) 
19 (47.5%) 
6 (15%) 
3 (7.5%) 
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Figure 1. Endoscopic findings: A- focal erythematous spots, B- erosions, C and D- deep ulcerations, 
E and F- stenosis and pseudopolyps 
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